Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

Clinical trials

Clinical trials

02-04-2018 | Rheumatoid arthritis | Article

Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: Results from the GO-MORE trial

Durez P et al. Clin Rheumatol 2018; Advance online publication. doi: 10.1007/s10067-018-4074-6

24-01-2018 | Pathogenesis | Review | Article

Moving towards a molecular taxonomy of autoimmune rheumatic diseases

Barturen G et al. Nat Rev Rheumatol 2018; 14: 75–93. doi: 10.1038/nrrheum.2017.220

13-12-2017 | Rheumatoid arthritis | Article

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries

Choy E et al. Rheumatology (Oxford) 2018; 57: 3. doi: 10.1093/rheumatology/kex443

07-04-2017 | Rheumatoid arthritis | Article

Diagnostic value of a 3-day course of prednisolone in patients with possible rheumatoid arthritis: The TryCort study

The results of the TryCort study demonstrate that the prednisolone test had a moderate sensitivity and a good specificity in differentiating between rheumatoid arthritis and hand osteoarthritis.

Kiltz U, von Zabern C, Baraliakos X et al. Arthritis Res Ther 2017;19:73. doi:10.1186/s13075-017-1279-z

Previous